Pharmasset Inc Business Profile
Pharmasset, Inc., a clinical-stage pharmaceutical company, engages in discovering, developing, and commercializing novel drugs to treat viral infections. The company primarily focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, inhibiting viral replication. The company has three clinical stage product candidates, including PSI-7977, an uracil nucleotide analog polymerase inhibitor, which is initiating a Phase III clinical trials; PSI-938, a guanine nucleotide analog polymerase inhibitor that is in Phase IIb clinical trials; and RG7128, a nucleoside analog polymerase inhibitor, which is in three Phase IIb clinical trials. It has a strategic collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the development of RG7128, and PSI-6130 and its prodrugs; and a collaboration and licensing agreement with Apath, LLC. Pharmasset, Inc. was founded in 1998 and is based in Princeton, New Jersey.
|No related news found for this Pharmasset Inc.|
Get our Stock Market & financial investment news alerts in your inbox